Parkinson

Bibliografia

Quali fonti bibliografiche considerare per il Parkinson?

Le informazioni contenute nella ricerca Pharmamedix dedicata al parkinson sono state analizzate con riferimento alle seguenti fonti.

1. Aarsland D. et al., Nat. Rev. Dis. Primers., 2021, 7 (1), 47.


2. Allen R.P. et a., Sleep Med., 2018, 41, 27.


3. Aminoff M.J. et al., Parkinsonism Relat. Disord., 2011, 17 (3), 139.


4. Armstrong M.J., Okun M.S., JAMA, 2020, 323 (6), 548.


5. Ascherio A., Schwarzschild M.A., Lancet Neurol., 2016, 15 (12), 1257.


6. Bandres-Ciga S. et al., Neurobiol. Dis., 2020, 137, 104782.


7. Bang M. et al., JAMA Netw. Open, 2025, 8 (10), e2535759.


8. Baron M.S., JAMA Netw. Open, 2025, 8 (10), e2535766.


9. Barone P. et al., Lancet Neurol., 2010, 9 (6), 573.


10. Beal M.F. et al., JAMA Neurol., 2014, 71 (5), 543.


11. Ben-Shlomo Y. et al., Lancet, 2024, 403 (10423), 283.


12. Berg D. et al., Mov. Disord., 2015, 30 (12), 1600. (Diagnosi)


13. Bisaglia M., Int. J. Mol. Sci., 2022, 24 (1), 42.


14. Blair H.A., CNS Drugs, 2025, 39 (6), 621.


15. Blauwendraat C. et al., Lancet Neurol., 2020, 19 (2), 170.


16. Bloem B.R. et al., Lancet, 2021, 397 (10291), 2284.


17. Brinker D. et al., Mov. Disord. Clin. Pract., 2024, 11 (3), 209.


18. Bull F.C. et al., Br. J. Sports Med., 2020, 54 (24), 1451.


19. Cattaneo C. et al., J. Parkinson Dis., 2016, 6 (1), 165.


20. Cheng Y, et al., Gut Microbes., 2023, 15 (2), 2284247.


21. Coukos R., Krainc D., Nat. Rev. Neurosci., 2024, 25 (6), 393.


22. Crotty G.F. et al., J. Parkinson Dis., 2024, 14 (s2), S381.


23. Cryan J,F. et al., Physiol. Rev., 2019, 99 (4), 1877.


24. De Bie R.M.A. et al., Mov. Disord., 2025, 40 (5), 776.


25. De Witt L.E. et al., Eur. Neuropsychopharmacol., 2022, 58, 30.


26. Deliz J.R. et al., Curr. Neurol. Neurosci. Rep., 2024, 24 (6), 163.


27. Deuschi G. et al., Eur. J. Neurol., 2022, 29 (9), 2580.


28. Dongning S. et al., BMJ, 2025, 388, e080952.


29. Dorsey E.R. et al., Lancet Neurol., 2025, 24 (11), 976.


30. Ernst M. et al., Cochrane database Syst. Rev., 2024, 4 (4), CD013856.


31. Fernandez H.H. et al., JAMA Neurol., 2026, 83 (5), 442.


32. Ferreira J.J. et al., Lancet Neurol., 2016, 15 (2), 154.


33. Focused Ultrasound Foundation Consensus, 2025 https://cdn.fusfoundation.org/2025/07/31085318/FUSF-State-of-the-Field-2025_July-31.pdf (accesso: luglio 2026).


34. Foltynie et al., Lancet, 2024, 403 (10423), 305.


35. Fox S.H. et al., Mov. Disord., 2018, 33 (8), 1248.


36. Grotewold N., Albin R.L., Parkinsonism Relat. Disord., 2024, 125, 107026.


37. Hamre H.J. et al., Syst. Rev., 2023, 12 (1), 191.


38. Hammoud F. et al., Parkinsons Dis., 2025, 2025, 1319419.


39. Hanson B.A. et al., JCI Insight, 2025, 10 (13), e189988.


40. Heinzel S. et al., Mov. Disord., 029, 34 (10), 1464.


41. Högl B. et al., Nat. Rev. Neurol., 2018, 14 (1), 40.


42. Höglinger G.U. et al., Lancet Neurol., 2024, 23 (2), 191.


43. Houser M.C., Tansey M.G., NPJ Parkinsons Dis., 2017, 3,3.


44. Howell M. et al., J. Clin. Sleep Med., 2023, 19 (4), 759.


45. Jankovic J., J. Neurol. Neurosurg. Psychiatry, 2008, 79 (4), 368.


46. Kalia L.V., Lang A.E., Lancet, 2015, 386 (9996), 896.


47. Kalia L.V. et al., Mov. Disord., 2024, 39 (10), 1710.


48. Katzenschlager R et al., J. Neurol. Neurosurg. Psychiatry, 2004, 75 (12), 1672.


49. Katzenschlager R. et al., Lancet Neurol., 2018, 17 (9), 749.


50. Kim T-H. et al., PLoS One, 2012, 7 (5), e35695.


51. Li S. et al., Evid. Based Complement. Alternat. Med., 2021, 2021, 5538200.


52. Lim S-Y. Et al., Lacet Neurol., 2024, 23 (12), 1267.


53. López-Jiménez A. et al., Sleep Med. Clin., 2025, 20 (3), 343.


54. Maggi G. et al., Sleep Med., 2024, 121, 275.


55. Mak M.K. et al., Nat. Rev. Neurol., 2017, 13 (11), 689.


56. Masci Walter, Omeopatia - Tradizione e attualità, 2003, Tecniche Nuove.


57. Meira B. et al., NPJ Parkinson Dis., 2021, 7 (1), 50.


58. Menozzi E. et al., Nat. Med., 2026, 32 (6), 2096.


59. Merghany R.M. et al., Naunyn. Schmiedebergs. Arch. Pharmacol., 2025, 398 (3), 2229.


60. Morbelli S. et al., Eur. J. Nucl. Med. Mol. Imaging, 2020, 47 (8), 1885.


61. Morris H.R. et al., Lancet, 2024, 403 (10423), 293.


62. Muller T., Neurodegener. Dis. Manag., 2022, 12 (1), 15.


63. Nalls M.A. et al., Lancet Neurol., 2015, 14 (10), 1002.


64. National Institute for Health and Care Excellence - NICE, 2024 https://www.nice.org.uk/guidance/ng71 (accesso: luglio 2026).


65. Neilson L.E. et al., JAMA Neurol., 2026, 83 (1), 68.


66. Ng M.G. et al., CNS Neurol. Disord. Drug Targets, 2024, 23 (6), 746.


67. Olanow C.W. et al., Lancet Neurol., 2014, 13 (2), 141.


68. Osborne J.A. et al., Phys. Ther., 2022, 102 (4), pzab302.


69. Pahwa R. et al., JAMA Neurol., 2017, 74 (8), 941.


70. Pahwa R. et al., JAMA Neurol., 2026, 83 (5), 452.


71. Parmar M. et al., Nat. Rev. Neurosci., 2020, 21 (2), 103.


72. Paul G. et al., Nat. Med., 2026, Jul 9. doi: 10.1038/s41591-026-04525-0.


73. PD MED Collaborative Group, Lancet, 2014, 384 (9949), 1196.


74. Postuma R.B. et al., Mov. Disord., 2015, 30 (12), 1591.


75. Postuma R.B. et al., Brain, 2019, 142 (3), 744.


76. Poewe W. et al., Nat. Rev. Dis. Primers., 2017, 3, 17013.


77. Ray S., Magnes. Pes., 2024, 36 (4), 69.


78. Reilly S. et al., Eur. J. Neurol., 2024, 31 (2), e16142.


79. Ren J. et al., Nature, 2026, 651 (8107), 1030.


80. Riccò M. et al., Acta Biomed., 2020, 91 (3), e2020088.


81. Schaeffer E. et al., Neurol. Res. Pract., 2026, 8 (1), 27.2026


82. Schapira A.H.V. et al., Nat. Rev. Neurosci., 2017, 18 (7), 435.


83. Scheperjans F. et al., JAMA Neurol., 2024, 81 (9), 925.


84. Schröter N. et al., J. Neural. Transm. (Vienna), 2024, 131 (11), 1285.


85. Schuepbach W.M.M. et al., NEJM, 2013, 368 (7), 610.


86. Seppi K. et al., Mov. Disord., 2019, 34 (2), 180.


87. Shang A. et al., Lancet, 366 (9487), 726.


88. Simonet C. et al., Pract. Neurol., 2020, 20 (1), 15.


89. Sisodia V. et al., BMJ Neurol. Open, 2024, 6 (1), e000573.


90. So Y-J. et al., Int. J. Mol. Sci., 2024, 25 (2), 1071.


91. Standaert D.G. et al., Mov. Disord. Clin. Pract., 2017, 4 (6), 829.


92. Stefani A., Högl B., Neuropsychopharmacology, 2020, 45 (1), 121.


93. Sawamoto N. et al., Nature, 2025, 641 (8064), 971.


94. Tabar V. et al., Nature, 2025, 641 (8064), 978.


95. Vallderiola F. et al., Parkinson Dis., 2015, 2015, 475630.


96. Vázquez-Vélez G.E. et al., Annu. Rev. Pathol., 2021, 44,87.


97. Veronese N. et al., Mov. Disord., 2024, 39 (7), 1203.


98. Verschuur C.V.M. et al., NEJM, 2019, 380 (4), 315.


99. Virmani T. et al., J. Clin. Mov. Disord., 2016, 3, 8.


100. Walach H. et al., J. Altern. Complement. Med., 2005, 11 (5), 813.


101. Wang Z. et al., J. Neurol., 2025, 272 (9), 567.


102. Weintraub D., Claassen D.O., Int. Rev. Neurobiol., 2017, 133, 679.


103. Winkelman J.W. et al., J. Clin. Sleep Med., 2025, 21 (1), 137.


104. World Health Organisation - WHO, 1993, Research guidelines for evaluating the safety and efficacy of herbal medicines.


105. Wu L. et al., Eur. J. Clin. Nutr., 2024, 78 (5), 365.


106. Yin W. et al., JAMA Neurol., 2025, 82 (7), 687.


107. Yoon S.Y., Brain Neurorehabil., 2022, 15 (2), e15.


108. Zhu J. et al., Lancet Healthy Longev., 2024, 5 (7), e464.